Overview Performance Dividends Peer Group Options

(ZIMV) ZimVie - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98888T1079

ZIMV: Dental, Implants, Biomaterials, Prosthetics, Instruments

ZimVie Inc. (NASDAQ:ZIMV) is a global medical technology company specializing in dental implant systems, biomaterials, and patient-specific restorative solutions. Founded in 2021 and headquartered in Palm Beach Gardens, Florida, the company operates through its Dental segment, offering a comprehensive portfolio of products and services designed to support dental tooth replacement and restoration procedures. ZimVies product lineup includes dental implant systems, bone grafts, barrier membranes, and collagen-based wound care products, as well as virtual treatment planning services, guided surgery solutions, and CAD/CAM workflow systems. The company also provides surgical instrumentation, kits, and patient-specific restorative solutions under the BellaTek brand, including abutments, bars, implant bridges, and hybrid restorations. Additionally, ZimVie offers Implant Concierge, a web-based treatment planning and surgery guide service.

ZimVies customer base includes oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, such as DSOs (Dental Service Organizations). The company also serves educational, medical, and governmental entities, hospitals, and surgery centers. Its products are distributed through a combination of direct sales representatives, agents, and distributors. With a global presence, ZimVie operates additional facilities worldwide to support its research, development, and manufacturing activities. The company is focused on advancing dental care through innovative solutions that combine clinical expertise with cutting-edge technology.

As of the latest data, ZimVie Inc. has a market capitalization of $361.55M, with a forward P/E ratio of 16.75, indicating expectations for future earnings growth. The companys P/B ratio of 0.90 suggests that its stock is trading near book value. However, the negative return on equity (RoE) of -85.50% highlights ongoing profitability challenges. The stock currently trades at $13.27, with a 20-day average price of $13.37 and a 50-day SMA of $13.73, slightly above the 200-day SMA of $15.74. The low ATR of 0.42 reflects limited price volatility.

Based on the technical and fundamental data, here is a 3-month forecast for ZimVie Inc.: - Price Trend: The stock is currently trading below its 20-day and 50-day SMAs, which may indicate short-term downward pressure. However, the 200-day SMA of $15.74 suggests potential long-term support. - Volatility: With an ATR of 0.42, price fluctuations are expected to remain moderate. - Earnings Outlook: The forward P/E of 16.75 indicates investor expectations for improved profitability, but the current negative RoE of -85.50% suggests significant challenges in achieving this. - Valuation: The P/S ratio of 0.80 is in line with industry peers, but the P/B ratio of 0.90 indicates undervaluation relative to book value. 3-Month Forecast: - Technical Outlook: The stock may experience sideways movement with potential stabilization near the 200-day SMA of $15.74. - Fundamental Outlook: ZimVies ability to improve profitability and reduce losses will be critical. If the company successfully executes its growth strategy, particularly in emerging markets and digital solutions, the stock could see a rebound. However, if profitability remains elusive, the stock may face downward pressure.

Additional Sources for ZIMV Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

ZIMV Stock Overview

Market Cap in USD 347m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 2022-03-01

ZIMV Stock Ratings

Growth 5y -47.3%
Fundamental -14.8%
Dividend 0.0%
Rel. Strength Industry -26.8
Analysts 3/5
Fair Price Momentum 10.60 USD
Fair Price DCF 6.25 USD

ZIMV Dividends

No Dividends Paid

ZIMV Growth Ratios

Growth Correlation 3m -67.4%
Growth Correlation 12m -74.7%
Growth Correlation 5y -2.9%
CAGR 5y -24.02%
CAGR/Max DD 5y -0.27
Sharpe Ratio 12m -0.09
Alpha -36.16
Beta 0.89
Volatility 64.73%
Current Volume 161.7k
Average Volume 20d 148.8k
What is the price of ZIMV stocks?
As of March 15, 2025, the stock is trading at USD 12.04 with a total of 161,747 shares traded.
Over the past week, the price has changed by -4.06%, over one month by -8.37%, over three months by -12.31% and over the past year by -26.18%.
Is ZimVie a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, ZimVie is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.75 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ZIMV as of March 2025 is 10.60. This means that ZIMV is currently overvalued and has a potential downside of -11.96%.
Is ZIMV a buy, sell or hold?
ZimVie has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold ZIMV.
  • Strong Buy: 0
  • Buy: 1
  • Hold: 1
  • Sell: 1
  • Strong Sell: 0
What are the forecast for ZIMV stock price target?
According to ValueRays Forecast Model, ZIMV ZimVie will be worth about 11.5 in March 2026. The stock is currently trading at 12.04. This means that the stock has a potential downside of -4.65%.
Issuer Forecast Upside
Wallstreet Target Price 18 49.5%
Analysts Target Price 18.7 55.1%
ValueRay Target Price 11.5 -4.7%